Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

We are committed to providing the media with timely and accurate information.

Media Contact:
Julie Normart
W2O Group
Jnormart@w2ogroup.com

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
09/13/16Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa™ (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that Phase 3 clinical data and preclinical data from studies of the Company’s Factor Xa inhibitor antidote AndexXaTM (andexanet alfa) will be presented in poster sessions at the upcoming 14th Annual Neurocritical Care Society Meeting, which will take place from September 15-18 in National Harbor, Md. Additionally, results of a retrospective chart review on treatment patte... 
Printer Friendly Version
08/30/16Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXA-4™ Study of Factor Xa Inhibitor Antidote AndexXa™ (andexanet alfa) in Patients with Acute Major Bleeding
--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours-- --Data Presented in Late-Breaking Science Hot Line Session at European Society of Cardiology 2016 Congress and Published in New England Journal of Medicine-- --Webcast with ANNEXA-4 Executive Committee Members Today at 11 a.m. ET-- SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:P... 
Printer Friendly Version
08/26/16Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress
Company to Host Webcast of Investor Event with Drs. Stuart J. Connolly and C. Michael Gibson to Discuss Data on Tuesday, August 30 SOUTH SAN FRANCISCO, Calif., Aug. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA™-4 trial of AndexXa™ (andexanet alfa), a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 ... 
Printer Friendly Version
08/19/16Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the MAA for IndexXa™ (andexanet alfa; trade name in the United States is AndexXa™), a Factor Xa inhibitor antidote, has been submitted to the EMA, completed the validation period, and has been accepted for review. IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled... 
Printer Friendly Version
08/17/16Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)
-- Conference call on August 18 at 8:30 am ET -- SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for AndexXa™ (andexanet alfa). An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or ... 
Printer Friendly Version
08/09/16Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the quarter ended June 30, 2016. “We made significant progress in the second quarter to advance our goal of commercializing multiple medicines that could change current medical practices for treating patients with thrombotic disorders and hematological cancers," said Bill Lis... 
Printer Friendly Version
08/02/16Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended June 30, 2016, and provide a general business overview on Tuesday, August 9, 2016, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Tuesday, August 9, 2016, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828... 
Printer Friendly Version
06/01/16Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib in... 
Printer Friendly Version
05/31/16Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37th Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc.  Port... 
Printer Friendly Version
05/27/16Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016-- --Webcast with APEX Study Executive Committee Members Today at 11 a.m. ET-- MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. , May 27, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking clinical trial... 
Printer Friendly Version
05/23/16Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
Webcast of Investor Event to Discuss Phase 3 APEX Data to be Held on Friday, May 27 SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpelli... 
Printer Friendly Version
05/05/16Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016. “During the first quarter of 2016, we continued to advance the development of our three product candidates. We reported acceptance of our ANDEXXA™ (andexanet alfa) BLA and Phase 3 topline data from the APEX trial of betrixaban, complete... 
Printer Friendly Version
04/28/16Portola Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5
SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2016, and provide a general business overview on Thursday, May 5, 2016, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 5... 
Printer Friendly Version
04/14/16Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development t... 
Printer Friendly Version
04/06/16Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016
SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that data from its Phase 3 APEX Study of betrixaban will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 62nd Annual SSC (Scientific and Standardization Committee) Meeting, which is taking place from May 25-28 in Montpellier, France. Portola is developing betrixaban, an oral Factor Xa inhibitor anticoagulant, for the prevention of venous thromboem... 
Printer Friendly Version
04/04/16Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan
Development and Commercialization of Andexanet Alfa In Japan Fully Supported by Collaboration Partners SOUTH SAN FRANCISCO, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that it has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan. Portola is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated... 
Printer Friendly Version
03/24/16Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
—Full Data Set to be Presented at International Society of Thrombosis and Haemostasis (ISTH) Congress in May— —Company to Hold Conference Call Today at 8:30 am ET— SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced topline data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared wi... 
Printer Friendly Version
03/24/16Portola Pharmaceuticals to Hold Conference Call on Thursday, March 24, at 8:30 am ET
SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a conference call today, Thursday, March 24, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), to provide a company update. Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 507-2588 internationally, and use the passcode 79012351. Please dial in 10 minutes prior to the start... 
Printer Friendly Version
03/01/16Portola Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 11:20 a.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharmaceutical... 
Printer Friendly Version
02/26/16Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
Conference Call Today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2015. “During the fourth quarter of 2015, we executed on several milestones that we expect will make 2016 a year of unprecedented progress. We plan to commercially launch andexanet alfa and report pivotal Phase 3 results from our APEX ... 
Printer Friendly Version
02/19/16Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, February 26
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2015, and provide a general business overview on Friday, February 26, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Can... 
Printer Friendly Version
02/17/16Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDA
--Target FDA Action Date is August 17, 2016-- SOUTH SAN FRANCISCO, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for andexanet alfa for filing under a priority review. Portola submitted the BLA in December 2015 under an Accelerated Approval pathway. The FDA is expected to take action ... 
Printer Friendly Version
02/01/16Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 Million
Portola Retains Full Worldwide Commercial Rights to Andexanet Alfa Outside of Japan SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc. to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaborat... 
Printer Friendly Version
01/08/16Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016
Two Products in Thrombosis Franchise Expected to Launch in Next 18 Months SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host an investor webcast to review its recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 12, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 34th Annual J.P. Morgan Healthcare Conference in... 
Printer Friendly Version